-
1
-
-
0031712063
-
Cyclosporin nephrotoxicity: Pathophysiology and comparison with FK-506
-
Ader JL and Rostaing L (1998) Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. Curr Opin Nephrol Hypertens 7:539-545.
-
(1998)
Curr Opin Nephrol Hypertens
, vol.7
, pp. 539-545
-
-
Ader, J.L.1
Rostaing, L.2
-
2
-
-
0024412071
-
Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine
-
Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388 -10395.
-
(1989)
J Biol Chem
, vol.264
, pp. 10388-10395
-
-
Aoyama, T.1
Yamano, S.2
Waxman, D.J.3
Lapenson, D.P.4
Meyer, U.A.5
Fischer, V.6
Tyndale, R.7
Inaba, T.8
Kalow, W.9
Gelboin, H.V.10
-
3
-
-
0033960105
-
Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions
-
Bader A, Hansen T, Kirchner G, Allmeling C, Haverich A, and Borlak JT (2000) Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 129:331-342.
-
(2000)
Br J Pharmacol
, vol.129
, pp. 331-342
-
-
Bader, A.1
Hansen, T.2
Kirchner, G.3
Allmeling, C.4
Haverich, A.5
Borlak, J.T.6
-
4
-
-
0027516405
-
Preparative chromatographic purification of cyclosporine metabolites
-
Brooks CA, Cramer SM, and Rosano TG (1993) Preparative chromatographic purification of cyclosporine metabolites. Clin Chem 39:457-466.
-
(1993)
Clin Chem
, vol.39
, pp. 457-466
-
-
Brooks, C.A.1
Cramer, S.M.2
Rosano, T.G.3
-
5
-
-
0025997099
-
Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity
-
Christians U, Kohlhaw K, Budniak J, Bleck JS, Schottmann R, Schlitt HJ, Almeida VM, Deters M, Wonigeit K, Pichlmayr R, et al. (1991) Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity. Eur J Clin Pharmacol 41:285-290.
-
(1991)
Eur J Clin Pharmacol
, vol.41
, pp. 285-290
-
-
Christians, U.1
Kohlhaw, K.2
Budniak, J.3
Bleck, J.S.4
Schottmann, R.5
Schlitt, H.J.6
Almeida, V.M.7
Deters, M.8
Wonigeit, K.9
Pichlmayr, R.10
-
6
-
-
4644280019
-
In vitro metabolism of cyclosporine A by human kidney CYP3A5
-
Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, and Thummel KE (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68:1889-1902.
-
(2004)
Biochem Pharmacol
, vol.68
, pp. 1889-1902
-
-
Dai, Y.1
Iwanaga, K.2
Lin, Y.S.3
Hebert, M.F.4
Davis, C.L.5
Huang, W.6
Kharasch, E.D.7
Thummel, K.E.8
-
7
-
-
0033023568
-
FK506 nephrotoxicity
-
Finn WF (1999) FK506 nephrotoxicity. Renal Fail 21:319-329.
-
(1999)
Renal Fail
, vol.21
, pp. 319-329
-
-
Finn, W.F.1
-
8
-
-
0041421011
-
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults
-
Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, and Watkins PB (2003) CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 95:1297-1300.
-
(2003)
J Appl Physiol
, vol.95
, pp. 1297-1300
-
-
Givens, R.C.1
Lin, Y.S.2
Dowling, A.L.3
Thummel, K.E.4
Lamba, J.K.5
Schuetz, E.G.6
Stewart, P.W.7
Watkins, P.B.8
-
9
-
-
12144286933
-
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
-
Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, and Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 147-154
-
-
Haufroid, V.1
Mourad, M.2
Van Kerckhove, V.3
Wawrzyniak, J.4
De Meyer, M.5
Eddour, D.C.6
Malaise, J.7
Lison, D.8
Squifflet, J.P.9
Wallemacq, P.10
-
10
-
-
0041831261
-
Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
-
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
-
(2003)
Clin Pharmacol Ther
, vol.74
, pp. 245-254
-
-
Hesselink, D.A.1
Van Schaik, R.H.2
Van Der Heiden, I.P.3
Van Der Werf, M.4
Gregoor, P.J.5
Lindemans, J.6
Weimar, W.7
Van Gelder, T.8
-
11
-
-
0033668287
-
Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells
-
Hortelano S, Castilla M, Torres AM, Tejedor A, and Bosca L (2000) Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells. J Am Soc Nephrol 11:2315-2323.
-
(2000)
J Am Soc Nephrol
, vol.11
, pp. 2315-2323
-
-
Hortelano, S.1
Castilla, M.2
Torres, A.M.3
Tejedor, A.4
Bosca, L.5
-
12
-
-
9444228347
-
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
-
Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
-
(2004)
Drug Metab Dispos
, vol.32
, pp. 1434-1445
-
-
Huang, W.1
Lin, Y.S.2
McConn II, D.J.3
Calamia, J.C.4
Totah, R.A.5
Isoherranen, N.6
Glodowski, M.7
Thummel, K.E.8
-
13
-
-
0030484996
-
Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid
-
Iwasaki K, Miyazaki Y, Teramura Y, Kawamura A, Tozuka Z, Hata T, and Undre N (1996) Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. Res Commun Mol Pathol Pharmacol 94:251-257.
-
(1996)
Res Commun Mol Pathol Pharmacol
, vol.94
, pp. 251-257
-
-
Iwasaki, K.1
Miyazaki, Y.2
Teramura, Y.3
Kawamura, A.4
Tozuka, Z.5
Hata, T.6
Undre, N.7
-
14
-
-
0028893714
-
Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506
-
Iwasaki K, Shiraga T, Matsuda H, Nagase K, Tokuma Y, Hata T, Fujii Y, Sakuma S, Fujitsu T, Fujikawa A, et al. (1995) Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 23:28-34.
-
(1995)
Drug Metab Dispos
, vol.23
, pp. 28-34
-
-
Iwasaki, K.1
Shiraga, T.2
Matsuda, H.3
Nagase, K.4
Tokuma, Y.5
Hata, T.6
Fujii, Y.7
Sakuma, S.8
Fujitsu, T.9
Fujikawa, A.10
-
15
-
-
0027518214
-
Isolation, identification and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone
-
Iwasaki K, Shiraga T, Nagase K, Tozuka Z, Noda K, Sakuma S, Fujitsu T, Shimatani K, Sato A, and Fujioka M (1993) Isolation, identification and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 21:971-977.
-
(1993)
Drug Metab Dispos
, vol.21
, pp. 971-977
-
-
Iwasaki, K.1
Shiraga, T.2
Nagase, K.3
Tozuka, Z.4
Noda, K.5
Sakuma, S.6
Fujitsu, T.7
Shimatani, K.8
Sato, A.9
Fujioka, M.10
-
16
-
-
0028917496
-
Pharmacokinetics of tacrolimus in liver transplant patients
-
Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, and Mekki QA (1995a) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57:281-290.
-
(1995)
Clin Pharmacol Ther
, vol.57
, pp. 281-290
-
-
Jusko, W.J.1
Piekoszewski, W.2
Klintmalm, G.B.3
Shaefer, M.S.4
Hebert, M.F.5
Piergies, A.A.6
Lee, C.C.7
Schechter, P.8
Mekki, Q.A.9
-
17
-
-
0028810418
-
Consensus document: Therapeutic monitoring of tacrolimus (FK-506)
-
Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE, Lieberman R, et al. (1995b) Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 17:606-614.
-
(1995)
Ther Drug Monit
, vol.17
, pp. 606-614
-
-
Jusko, W.J.1
Thomson, A.W.2
Fung, J.3
McMaster, P.4
Wong, S.H.5
Zylber-Katz, E.6
Christians, U.7
Winkler, M.8
Fitzsimmons, W.E.9
Lieberman, R.10
-
18
-
-
23044476217
-
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus
-
Kamdem LK, Streit F, Zanger UM, Brockmöller J, Oellerich M, Armstrong VW, and Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374-1381.
-
(2005)
Clin Chem
, vol.51
, pp. 1374-1381
-
-
Kamdem, L.K.1
Streit, F.2
Zanger, U.M.3
Brockmöller, J.4
Oellerich, M.5
Armstrong, V.W.6
Wojnowski, L.7
-
19
-
-
0035349064
-
Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy
-
Kempkes-Koch M, Fobker M, Erren M, August C, Gerhardt U, Suwelack B, and Hohage H (2001) Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy. Transplant Proc 33:2167-2169.
-
(2001)
Transplant Proc
, vol.33
, pp. 2167-2169
-
-
Kempkes-Koch, M.1
Fobker, M.2
Erren, M.3
August, C.4
Gerhardt, U.5
Suwelack, B.6
Hohage, H.7
-
20
-
-
0000574406
-
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
-
Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
-
(1998)
Biochemistry
, vol.37
, pp. 4137-4147
-
-
Korzekwa, K.R.1
Krishnamachary, N.2
Shou, M.3
Ogai, A.4
Parise, R.A.5
Rettie, A.E.6
Gonzalez, F.J.7
Tracy, T.S.8
-
21
-
-
6944230851
-
The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients
-
Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, and Beige J (2004) The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14:665-671.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 665-671
-
-
Kreutz, R.1
Zurcher, H.2
Kain, S.3
Martus, P.4
Offermann, G.5
Beige, J.6
-
22
-
-
0035071598
-
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
-
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
-
(2001)
Nat Genet
, vol.27
, pp. 383-391
-
-
Kuehl, P.1
Zhang, J.2
Lin, Y.3
Lamba, J.4
Assem, M.5
Schuetz, J.6
Watkins, P.B.7
Daly, A.8
Wrighton, S.A.9
Hall, S.D.10
-
24
-
-
0029560982
-
Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions and interindividual variability
-
Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, and Sewing KF (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 23:1315-1324.
-
(1995)
Drug Metab Dispos
, vol.23
, pp. 1315-1324
-
-
Lampen, A.1
Christians, U.2
Guengerich, F.P.3
Watkins, P.B.4
Kolars, J.C.5
Bader, A.6
Gonschior, A.K.7
Dralle, H.8
Hackbarth, I.9
Sewing, K.F.10
-
25
-
-
0034853228
-
In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry
-
Lhoest G, Hertsens R, Verbeeck RK, Maton N, Wallemacq P, Dehoux JP, and Latinne D (2001) In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry. J Mass Spectrom 36:889-901.
-
(2001)
J Mass Spectrom
, vol.36
, pp. 889-901
-
-
Lhoest, G.1
Hertsens, R.2
Verbeeck, R.K.3
Maton, N.4
Wallemacq, P.5
Dehoux, J.P.6
Latinne, D.7
-
26
-
-
0036089341
-
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
-
Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
-
(2002)
Mol Pharmacol
, vol.62
, pp. 162-172
-
-
Lin, Y.S.1
Dowling, A.L.2
Quigley, S.D.3
Farin, F.M.4
Zhang, J.5
Lamba, J.6
Schuetz, E.G.7
Thummel, K.E.8
-
27
-
-
0035133672
-
The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
-
Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, and Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24-31.
-
(2001)
Clin Pharmacol Ther
, vol.69
, pp. 24-31
-
-
Mancinelli, L.M.1
Frassetto, L.2
Floren, L.C.3
Dressler, D.4
Carrier, S.5
Bekersky, I.6
Benet, L.Z.7
Christians, U.8
-
28
-
-
0032586718
-
The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects
-
Moller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T, Schafer A, and Undre NA (1999) The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 27:633-636.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 633-636
-
-
Moller, A.1
Iwasaki, K.2
Kawamura, A.3
Teramura, Y.4
Shiraga, T.5
Hata, T.6
Schafer, A.7
Undre, N.A.8
-
29
-
-
0033042397
-
Cytochrome P450 CYP3A in human renal cell cancer
-
Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, and Melvin WT (1999) Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79:1836-1842.
-
(1999)
Br J Cancer
, vol.79
, pp. 1836-1842
-
-
Murray, G.I.1
McFadyen, M.C.2
Mitchell, R.T.3
Cheung, Y.L.4
Kerr, A.C.5
Melvin, W.T.6
-
30
-
-
0028204924
-
Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes
-
Nagase K, Iwasaki K, Nozaki K, and Noda K (1994) Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 46:113-117.
-
(1994)
J Pharm Pharmacol
, vol.46
, pp. 113-117
-
-
Nagase, K.1
Iwasaki, K.2
Nozaki, K.3
Noda, K.4
-
31
-
-
0034835463
-
Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans
-
Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316 -1324.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 1316-1324
-
-
Naritomi, Y.1
Terashita, S.2
Kimura, S.3
Suzuki, A.4
Kagayama, A.5
Sugiyama, Y.6
-
32
-
-
0035987898
-
Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach
-
Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 831-837
-
-
Obach, R.S.1
Reed-Hagen, A.E.2
-
33
-
-
0042360213
-
Chronic renal failure after transplantation of a nonrenal organ
-
Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, and Merion RM (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:931-940.
-
(2003)
N Engl J Med
, vol.349
, pp. 931-940
-
-
Ojo, A.O.1
Held, P.J.2
Port, F.K.3
Wolfe, R.A.4
Leichtman, A.B.5
Young, E.W.6
Arndorfer, J.7
Christensen, L.8
Merion, R.M.9
-
34
-
-
0031445547
-
Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism
-
Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
-
(1997)
J Pharmacol Exp Ther
, vol.283
, pp. 1552-1562
-
-
Paine, M.F.1
Khalighi, M.2
Fisher, J.M.3
Shen, D.D.4
Kunze, K.L.5
Marsh, C.L.6
Perkins, J.D.7
Thummel, K.E.8
-
35
-
-
0026662551
-
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
-
Sattler M, Guengerich FP, Yun CH, Christians U, and Sewing KF (1992) Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-761.
-
(1992)
Drug Metab Dispos
, vol.20
, pp. 753-761
-
-
Sattler, M.1
Guengerich, F.P.2
Yun, C.H.3
Christians, U.4
Sewing, K.F.5
-
36
-
-
0038237028
-
Tacrolimus: A further update of its use in the management of organ transplantation
-
Scott LJ, McKeage K, Keam SJ, and Plosker GL (2003) Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63:1247-1297.
-
(2003)
Drugs
, vol.63
, pp. 1247-1297
-
-
Scott, L.J.1
McKeage, K.2
Keam, S.J.3
Plosker, G.L.4
-
37
-
-
0028295725
-
Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes
-
Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, and Funae Y (1994) Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47:727-735.
-
(1994)
Biochem Pharmacol
, vol.47
, pp. 727-735
-
-
Shiraga, T.1
Matsuda, H.2
Nagase, K.3
Iwasaki, K.4
Noda, K.5
Yamazaki, H.6
Shimada, T.7
Funae, Y.8
-
38
-
-
0242332169
-
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
-
Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235.
-
(2003)
Transplantation
, vol.76
, pp. 1233-1235
-
-
Thervet, E.1
Anglicheau, D.2
King, B.3
Schlageter, M.H.4
Cassinat, B.5
Beaune, P.6
Legendre, C.7
Daly, A.K.8
-
39
-
-
0024521323
-
Isolation, characterization and in vitro activity of human cyclosporin A metabolites
-
Wallemacq PE, Lhoest G, Latinne D, and De Bruyere M (1989) Isolation, characterization and in vitro activity of human cyclosporin A metabolites. Transplant Proc 21:906-910.
-
(1989)
Transplant Proc
, vol.21
, pp. 906-910
-
-
Wallemacq, P.E.1
Lhoest, G.2
Latinne, D.3
De Bruyere, M.4
-
40
-
-
0037693831
-
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
-
Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483.
-
(2003)
Am J Transplant
, vol.3
, pp. 477-483
-
-
Zheng, H.1
Webber, S.2
Zeevi, A.3
Schuetz, E.4
Zhang, J.5
Bowman, P.6
Boyle, G.7
Law, Y.8
Miller, S.9
Lamba, J.10
|